HENLIUS (02696) saw its shares rise by nearly 7% during the morning trading session. As of the time of writing, the stock was up 6.21%, trading at HKD 70.1, with a turnover of HKD 12.1671 million.

The movement follows a company announcement that the first patient in China (excluding Hong Kong, Macau, and Taiwan) has been dosed in a Phase 1b/2 clinical study evaluating HLX701, a recombinant human SIRPα-IgG4 Fc fusion protein injection, in combination with cetuximab and chemotherapy for the treatment of advanced colorectal cancer.

Additionally, HENLIUS recently received marketing approval from Health Canada for its denosumab biosimilar, BILDYOS, and for TUZEMTY.

Of note, the company reported that its full-year 2025 revenue increased by 16.5% year-over-year to RMB 6.67 billion, with a net profit attributable to shareholders of RMB 827 million.

According to an analysis by Shenwan Hongyuan, driven by increased sales of core products such as Han Qu You and Han Si Zhuang, coupled with rapid growth in overseas revenue, the company's total global product revenue for 2025 reached RMB 5.82 billion, representing a 17.8% increase year-over-year. Specifically, global revenue for Han Qu You and Han Si Zhuang were RMB 2.99 billion (up 6.5% year-over-year) and RMB 1.50 billion (up 14.0% year-over-year), respectively. Furthermore, the company's overseas product revenue exceeded RMB 200 million, marking a growth of over 100% compared to the previous year.